Pink Sheet is part of the Business Intelligence Division of Informa PLC

This site is operated by a business or businesses owned by Informa PLC and all copyright resides with them. Informa PLC’s registered office is 5 Howick Place, London SW1P 1WG. Registered in England and Wales. Number 8860726.

This copy is for your personal, non-commercial use. For high-quality copies or electronic reprints for distribution to colleagues or customers, please call +44 (0) 20 3377 3183

Printed By


Celgene Sets Sights On Becoming Inflammation and Immunology Power Player

Executive Summary

Celgene will buy Receptos for $7.2 billion, gaining the late-stage drug ozanimod in development for multiple sclerosis and ulcerative colitis. With the addition of ozanimod, the company will have three late-stage drugs in its inflammation and immunology portfolio.


Related Content

Celgene Plots Blockbuster Course For Ozanimod
Celgene IBD Pipeline In Question As Mongersen Crohn’s Disease Trial Ends
Celgene's Positive Ozanimod Data Puts Focus On MS Commercialization
Neuroscience Reaches A New Inflection Point, Big Biotechs Say
Celgene’s Otezla Shines, On Track To Be A Fourth Blockbuster Pillar
Celgene Diversifying Beyond Myeloma Backbone Revlimid
Deal Watch: Immunocore Raises Biggest EU Financing, $320M, For TCR Biologics Program
Celgene Oncology Strategy: Seizing The Immuno-Hematology Opportunity
Celgene Makes A Play For Inflammation & Immunology Stake With Apremilast


Related Companies

Related Deals




Ask The Analyst

Please Note: You can also Click below Link for Ask the Analyst
Ask The Analyst

Your question has been successfully sent to the email address below and we will get back as soon as possible. my@email.address.

All fields are required.

Please make sure all fields are completed.

Please make sure you have filled out all fields

Please make sure you have filled out all fields

Please enter a valid e-mail address

Please enter a valid Phone Number

Ask your question to our analysts